Last reviewed · How we verify
Gabapentin Pill
Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters in the nervous system.
Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters in the nervous system. Used for Postherpetic neuralgia, Partial-onset seizures (adjunctive therapy), Neuropathic pain.
At a glance
| Generic name | Gabapentin Pill |
|---|---|
| Also known as | Oral gabapentin |
| Sponsor | Shanghai Zhongshan Hospital |
| Drug class | Anticonvulsant / Gabapentinoid |
| Target | Alpha-2-delta subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Gabapentin is a gabaminergic compound that crosses the blood-brain barrier and binds to calcium channel subunits on presynaptic neurons. This binding decreases calcium influx and subsequently reduces the release of neurotransmitters such as glutamate, noradrenaline, and substance P. The net effect is a reduction in neuronal excitability and pain signal transmission.
Approved indications
- Postherpetic neuralgia
- Partial-onset seizures (adjunctive therapy)
- Neuropathic pain
Common side effects
- Dizziness
- Somnolence
- Ataxia
- Fatigue
- Peripheral edema
Key clinical trials
- Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction. (PHASE4)
- Gabapentin to Reduce Alcohol and Improve Viral Load Suppression (PHASE2)
- Efficacy of Methylprednisolone for Pain Control After ACL Repair (PHASE4)
- Predicting, Understanding and Speeding Recovery After TKA (PHASE4)
- Hip Arthroscopy Postoperative Opioid Demands (NA)
- Emergency Department-Initiated Medications for Alcohol Use Disorder (PHASE3)
- Gabapentin and Tizanidine for Insomnia in Chronic Pain (PHASE2)
- Effect of Gabapentin on Sleep and Opioid Use Following Rotator Cuff Repair (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gabapentin Pill CI brief — competitive landscape report
- Gabapentin Pill updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI